ARAV - Aravive Inc Stock Price, Fair Value and News

0.04USD Market Closed

Market Summary

USD0.04

Market Closed

ARAV Stock Price

View Fullscreen

ARAV RSI Chart

ARAV Valuation

Market Cap

2.9M

Price/Earnings (Trailing)

-0.07

Price/Sales (Trailing)

0.42

EV/EBITDA

0.04

Price/Free Cashflow

-0.05

ARAV Price/Sales (Trailing)

ARAV Profitability

EBT Margin

-807.23%

Return on Equity

-2.3K%

Return on Assets

-305.36%

Free Cashflow Yield

-2.0K%

ARAV Fundamentals

ARAV Revenue

Revenue (TTM)

7.0M

Rev. Growth (Yr)

-44.39%

Rev. Growth (Qtr)

116.33%

ARAV Earnings

Earnings (TTM)

-39.8M

Earnings Growth (Yr)

235.52%

Earnings Growth (Qtr)

17.87%

Breaking Down ARAV Revenue

Last 30 days

-66.7%

Last 90 days

-71.4%

Trailing 12 Months

-97.6%

How does ARAV drawdown profile look like?

ARAV Financial Health

Current Ratio

0.98

ARAV Investor Care

Shares Dilution (1Y)

22.96%

Diluted EPS (TTM)

-0.96

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	9.5M	9.2M	7.0M	0
2022	8.3M	6.1M	8.6M	9.1M
2021	6.1M	6.6M	7.0M	7.4M
2020	0	0	0	5.7M
2019	25.9M	18.9M	11.8M	4.8M
2018	0	0	0	33.0M
2017	0	0	0	40.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Aravive Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Oct 24, 2022	zhang eric	acquired	500,000	0.9199	543,537	-
Oct 24, 2022	ho peter tai-ching	acquired	49,999	0.9199	54,353	-
Oct 24, 2022	giaccia amato	acquired	249,999	0.9199	271,768	-
Oct 24, 2022	mcintyre gail frances	acquired	49,999	0.9199	54,353	ceo and president
Oct 24, 2022	howard rudy	acquired	9,999	0.9199	10,870	chief financial officer
Oct 24, 2022	eshelman fredric n	acquired	15,000,000	0.9199	16,306,100	executive chairman
Apr 01, 2022	eshelman fredric n	acquired	454	0.0001	4,545,460	executive chairman of board
Mar 29, 2022	eshelman fredric n	acquired	2,000,000	2.325	860,216	executive chairman of board

Which funds bought or sold ARAV recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	BNP PARIBAS FINANCIAL MARKETS	sold off	-100	-43.00	-	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	sold off	-100	-3,000	-	-%
Apr 09, 2024	COLLECTIVE FAMILY OFFICE LLC	sold off	-100	-1,856	-	-%
Apr 09, 2024	MASSMUTUAL TRUST CO FSB/ADV	unchanged	-	-777	373	-%
Mar 11, 2024	VANGUARD GROUP INC	reduced	-3.93	-15,000	135,414	-%
Feb 26, 2024	Virtu Financial LLC	reduced	-58.25	-7,000	5,000	-%
Feb 16, 2024	GSA CAPITAL PARTNERS LLP	new	-	245,000	245,000	0.02%
Feb 15, 2024	JANE STREET GROUP, LLC	new	-	1,596	1,596	-%
Feb 14, 2024	STATE STREET CORP	unchanged	-	-658	9,795	-%

Are Funds Buying or Selling ARAV?

Are funds buying ARAV calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ARAV

No. of Funds

Unveiling Aravive Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	biotechnology value fund l p	7.1%	5,664,238	SC 13G/A
Feb 14, 2024	baker bros. advisors lp	4.99%	3,863,568	SC 13G/A
Feb 09, 2024	artal international s.c.a.	9.4%	7,609,522	SC 13G/A
Feb 14, 2023	baker bros. advisors lp	7.5%	4,586,404	SC 13G
Feb 13, 2023	artal international s.c.a.	9.9%	12,182,037	SC 13G/A
Dec 28, 2022	zhang eric	3.4%	2,029,634	SC 13D/A
Dec 27, 2022	giaccia amato	2.9%	1,725,244	SC 13D/A
Nov 07, 2022	biotechnology value fund l p	6.4%	3,908,320	SC 13G
Nov 03, 2022	eshelman ventures, llc	43.5%	26,378,105	SC 13D/A
Apr 05, 2022	eshelman fredric n	33.9%	10,071,985	SC 13D/A

Recent SEC filings of Aravive Inc

View All Filings

Date Filed	Form Type	Document
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 09, 2024	SC 13G/A	Major Ownership Report
Feb 08, 2024	15-12G	15-12G
Feb 01, 2024	EFFECT	EFFECT
Feb 01, 2024	EFFECT	EFFECT
Feb 01, 2024	EFFECT	EFFECT
Feb 01, 2024	EFFECT	EFFECT
Feb 01, 2024	EFFECT	EFFECT
Jan 29, 2024	POS AM	POS AM

Peers (Alternatives to Aravive Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.1B	6.8B	21.21%	-3.50%	-8.06	7.03	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.0B	2.0B	-0.48%	-24.66%	-57.25	9.49	75.20%	68.82%
BMRN	15.9B	2.5B	-3.50%	-10.49%	77.41	6.43	13.74%	186.89%
INCY	11.9B	3.8B	-4.91%	-21.97%	15.99	3.16	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-14.74%	-44.14%	-10.83	14.44	425.83%	18.94%
BBIO	5.2B	107.9M	-3.68%	92.64%	-9.5	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	-0.50%	3.10%	-14.69	12.99	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.87%	-39.98%	-10.07	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-5.69%	-19.43%	-45.92	3.87	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-1.57%	-9.52%	24.79	4.45	85.90%	-14.05%
NVAX	659.2M	983.7M	3.97%	-34.13%	-1.21	0.67	-50.36%	17.16%
CRBP	400.8M	881.7K	1.98%	349.41%	-8.99	466.16	-77.61%	-5.33%
INO	280.7M	4.9M	-3.22%	25.10%	-2.08	57.68	-54.97%	51.71%
IBIO	7.0M	2.1M	-29.72%	84.40%	-0.26	2.14	-13.45%	66.37%

Aravive Inc News

Latest updates

Aravive Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2017Q4
Revenue	116.3%	2,756,000	1,274,000	1,491,000	1,474,000	4,956,000	1,615,000	1,092,000	985,000	2,412,000	3,789,000	2,526,000	1,263,000	-	-	3,054,000	1,699,000	20,849,500	40,000,000
Operating Expenses	-15.8%	11,670,000	13,860,000	19,404,000	21,338,000	21,504,000	21,042,000	16,090,000	14,641,500	13,986,000	11,200,000	8,264,000	9,734,500	5,163,000	6,998,000	6,928,000	7,438,000	52,607,000	8,886,000
S&GA Expenses	-4.2%	2,940,000	3,070,000	3,489,000	3,385,000	2,836,000	3,727,000	3,088,000	2,447,500	2,643,000	3,080,000	2,380,000	3,198,500	2,652,000	3,158,000	3,291,000	4,590,000	11,284,000	7,569,000
R&D Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,840,000	3,637,000	2,848,000	3,010,000	1,317,000
EBITDA Margin	-31.4%	-7.60	-5.78	-5.57	-5.82	-6.15	-8.70	-6.41	-7.13	-7.58	-8.05	-8.51	-9.18	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-375,000
Earnings Before Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-70,821,000	30,753,000
EBT Margin	-31.5%	-8.07	-6.14	-5.92	-6.18	-6.53	-9.25	-6.82	-7.59	-8.06	-8.60	-9.22	-9.93	-	-	-	-	-	-
Net Income	17.9%	21,226,000	18,008,000	-49,956,000	-29,125,000	-15,663,000	-18,477,000	-13,057,000	-12,956,000	-11,086,000	-7,105,000	-8,004,000	-4,046,000	-4,328,000	-6,142,000	-3,044,000	-4,704,000	-50,954,000	31,128,000
Net Income Margin	31.7%	-5.70	-8.35	-11.87	-8.35	-6.96	-9.10	-5.34	-5.26	-4.32	-4.54	-4.53	-5.37	-	-	-	-	-	-
Free Cashflow	52.8%	-7,021,000	-14,869,000	-14,965,000	-11,449,000	-16,145,000	-16,234,000	-10,103,000	-5,556,000	-5,876,000	-2,365,000	-7,232,000	7,011,000	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Assets	-49.3%	13.00	26.00	43.00	62.00	42.00	56.00	74.00	68.00	77.00	85.00	87.00	68.00	61.00	71.00	72.00	82.00	63.00	67.00	72.00	69.00	74.00
Current Assets	-56.6%	10.00	22.00	39.00	58.00	38.00	51.00	69.00	63.00	72.00	80.00	81.00	62.00	55.00	61.00	61.00	68.00	48.00	52.00	57.00	58.00	63.00
Cash Equivalents	-53.6%	9.00	18.00	36.00	54.00	28.00	47.00	66.00	59.00	68.00	75.00	79.00	61.00	54.00	60.00	63.00	68.00	47.00	51.00	58.00	59.00	65.00
Net PPE	-18.1%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	0.00	-
Liabilities	-75.1%	11.00	46.00	82.00	51.00	27.00	26.00	35.00	26.00	22.00	21.00	19.00	20.00	12.00	12.00	13.00	13.00	15.00	14.00	17.00	10.00	10.00
Current Liabilities	-31.2%	10.00	14.00	20.00	22.00	24.00	21.00	20.00	18.00	14.00	12.00	9.00	9.00	5.00	5.00	5.00	5.00	6.00	5.00	7.00	2.00	3.00
Shareholder's Equity	-	2.00	-	-	11.00	15.00	30.00	39.00	42.00	54.00	64.00	69.00	48.00	49.00	59.00	59.00	69.00	48.00	53.00	55.00	60.00	64.00
Retained Earnings	3.3%	-626	-648	-666	-616	-587	-571	-552	-539	-526	-515	-508	-500	-496	-485	-480	-470	-465	-459	-456	1.00	-399
Additional Paid-In Capital	0.0%	629	628	627	627	602	601	592	582	581	580	577	549	546	545	540	539	513	513	512	511	463
Shares Outstanding	22.9%	74.00	60.00	60.00	60.00	31.00	31.00	24.00	21.00	21.00	21.00	20.00	16.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	19.00	-	-	-	89.00	-	-	-	141	-	-	-	45.00	-	-	-

Cashflow (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Cashflow From Operations	44.4%	-9,808	-17,656	-17,752	-14,236	-18,932	-19,021	-12,890	-8,343	-8,663	-5,152	-10,019	4,224	-6,297	-5,634	-4,462	-5,072	-3,401	-7,212	-1,396	-8,777	-5,184
Share Based Compensation	-61.6%	292	761	688	576	639	725	620	585	627	540	505	385	376	488	717	610	800	941	1,048	9,850	1,313
Cashflow From Investing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,272	-
Cashflow From Financing	-100.0%	-	25.00	-	40,049	-	29.00	19,291	257	737	1,907	28,160	2,350	203	4,997	33.00	25,236	1.00	-	-	-	17.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ARAV Income Statement

2023-09-30

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenue
Total revenue	$ 2,756	$ 4,956	$ 5,520	$ 7,663
Operating expenses
Research and development	8,730	18,668	35,435	48,985
General and administrative	2,940	2,836	9,499	9,651
Total operating expenses	11,670	21,504	44,934	58,636
Loss from operations	(8,914)	(16,548)	(39,414)	(50,973)
Other income (expense), net:
Interest income	209	147	1,028	220
Change in fair value of warrant liability	29,231	0	25,616	1,410
Other income, net	700	738	2,048	2,146
Total other income (expense), net	30,140	885	28,692	3,776
Net income (loss)	$ 21,226	$ (15,663)	$ (10,722)	$ (47,197)
Net income (loss) per share
Basic (in dollars per share)	$ 0.28	$ (0.51)	$ (0.14)	$ (1.72)
Diluted (in dollars per share)	$ 0.28	$ (0.51)	$ (0.38)	$ (1.72)
Weighted-average shares used to compute net income (loss) per share
Basic (in shares)	75,739	30,518	75,727	27,419
Diluted (in shares)	76,093	30,518	95,441	27,419
Collaborative Arrangement [Member]
Revenue
Total revenue	$ 2,756	$ 4,956	$ 5,520	$ 7,663

ARAV Balance Sheet

2023-09-30

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current Assets
Cash and cash equivalents	$ 8,535	$ 53,689
Prepaid expenses and other current assets	1,027	4,281
Total current assets	9,562	57,970
Restricted cash	2,408	2,445
Property and equipment, net	167	270
Operating lease right-of-use assets	907	1,462
Other assets	5	6
Total assets	13,049	62,153
Current liabilities
Accounts payable	5,423	8,765
Accrued liabilities	2,233	6,738
Operating lease obligation, current portion	2,121	2,195
Current portion of deferred revenue	0	4,414
Total current liabilities	9,777	22,112
Deferred revenue, net of current portion	0	621
Operating lease obligation, net of current portion	306	1,882
Warrant liability	1,265	26,881
Total liabilities	11,348	51,496
Commitments and contingencies (Note 6)
Stockholders' equity
Common stock, $0.0001 par value, 250,000,000 shares authorized at September 30, 2023 and 100,000,000 shares authorized at December 31, 2022; 73,562,648 shares issued and outstanding at September 30, 2023 and 59,844,850 shares issued and outstanding at December 31, 2022	7	6
Additional paid-in capital	628,543	626,778
Accumulated deficit	(626,849)	(616,127)
Total stockholders' equity	1,701	10,657
Total liabilities and stockholders’ equity	$ 13,049	$ 62,153

About Aravive Inc

Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.

CEO	Dr. Gail F. McIntyre CH (ASCP), DABT, Ph.D.
WEBSITE	https://aravive.com
INDUSTRY	Biotechnology
EMPLOYEES	23

Aravive Inc Frequently Asked Questions

What is the ticker symbol for Aravive Inc? What does ARAV stand for in stocks?

ARAV is the stock ticker symbol of Aravive Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aravive Inc (ARAV)?

As of Wed Feb 07 2024, market cap of Aravive Inc is 2.94 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ARAV stock?

You can check ARAV's fair value in chart for subscribers.

What is the fair value of ARAV stock?

You can check ARAV's fair value in chart for subscribers. The fair value of Aravive Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aravive Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ARAV so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aravive Inc a good stock to buy?

The fair value guage provides a quick view whether ARAV is over valued or under valued. Whether Aravive Inc is cheap or expensive depends on the assumptions which impact Aravive Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ARAV.

What is Aravive Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Feb 07 2024, ARAV's PE ratio (Price to Earnings) is -0.07 and Price to Sales (PS) ratio is 0.42. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ARAV PE ratio will change depending on the future growth rate expectations of investors.